New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
09:07 EDTJMEI, SKH, DKS, PWRD, CYTX, RAX, ARO, BHP, PDLI, RDEN, HD, ONTYOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Home Depot (HD), up 3.8%... Aeropostale (ARO), up 12%... Dick's Sporting (DKS), up 5.3%... PDL BioPharma (PDLI), up 5.7%. HIGHER: Skilled Healthcare (SKH), up 27.2% after combining with Genesis HealthCare In 100% stock deal... Cytori Therapeutics (CYTX), up 8% after BARDA executes contract option with the company valued at $12.1M... Rackspace (RAX), up 3.2% after Blue Harbour reported a 6.4% stake in the company. DOWN AFTER EARNINGS: Elizabeth Arden (RDEN), down 23.3%... Jumei (JMEI), down 3.5%... Perfect World (PWRD), down 2.4%. LOWER: Oncothyreon (ONTY), down 14.4% after announcing that EMR 63325-009 study did not its meet primary endpoint... BHP Billiton (BHP), down 3% after announcing the demerger of its metals and mining company to be completed in 1H15...
News For HD;ARO;DKS;RDEN;RAX;SKH;PDLI;CYTX;JMEI;BHP;PWRD;ONTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
05:46 EDTBHPStocks with implied volatility movement; BHP MAT
Subscribe for More Information
February 4, 2016
16:18 EDTRDENElizabeth Arden reports Q2 adjusted EPS 10c
Subscribe for More Information
11:46 EDTBHPOptions with increasing put volume
Subscribe for More Information
11:21 EDTBHPOptions with increasing call volume; FMC HST XME RIO BHP PAY DNDK BSX ALLY SWFT
February 3, 2016
19:47 EDTHDHome Depot to hire 2,000 employees in Massachusetts, Boston Globe says
Subscribe for More Information
07:35 EDTHDHome Depot hiring over 80,000 positions for spring
Home Depot is hiring more than 80,000 associates nationwide to ensure its stores are staffed for the company's busiest selling season.
07:15 EDTCYTXCytori says Cytori Cell Therapy 'safe' and 'effective' in EU Phase 1 ED trial
Subscribe for More Information
February 2, 2016
06:43 EDTBHPBHP may lose 'solid A' status amid commodities rout, Bloomberg says
Subscribe for More Information
February 1, 2016
19:09 EDTPDLIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Alphabet (GOOG, GOOGL), up 5.2% and 4.7%, respectively... Mattel (MAT), up 5.6%... Anadarko Petroleum (APC), up 4%... AFLAC (AFL), up 1.5%. ALSO HIGHER: PVH Corp. (PVH), up 8.1% after giving guidance for fiscal 2015 and entering a license agreement with G-III Apparel (GIII) for Tommy Hilfiger womenswear collections. DOWN AFTER EARNINGS: Integrated Device (IDTI), down 15.8%... Rent-A-Center (RCII), down 9.6%. ALSO LOWER: Pixelworks (PXLW), down 5.7% after giving fourth quarter guidance and announcing the resignation of its CEO... PDL BioPharma (PDLI), down 14.3% after cutting its quarterly dividend to 5c per share from 15c per share.
17:25 EDTPDLIPDL BioPharma lowers quarterly dividend to 5c per share from 15c per share
PDL Biopharma announced that its board has declared a 5c per share dividend for Q1. The dividend will be paid on March 11, to all stockholders who own shares of PDL on March 4, the record date for Q1 dividend payment. The company believes PDL's prospects in 2016 are very strong. In particular, factors the board assessed to determine the dividend payment amount included: The need to retain a sizeable cash position in order to capitalize on potential income-generating deals that could provide significantly greater long-term benefits to the company and its shareholders. In particular, PDL already has seen an increase in deal flow as companies are impacted by the broader equity and debt market shift to less favorable terms. The expiration of the Queen et al. patents associated with a number of PDL's revenue-generating assets. In preparation and to mitigate the impact, the Company has committed more than $1B to acquire other income generating assets not covered by these patents that should continue to generate income for PDL. As expected, the impact of the expiration of Queen et al. patents will begin to be reflected with Q2 revenues. The vast majority of companies that pay dividends evaluate their dividend disbursements on a quarterly, rather than annual basis. Based on PDL's research, PDL was only one of two companies out of 308 that employed the annual assessment. PDL will now adopt the more common practice of announcing its dividend payout on a quarterly basis in order to better evaluate alternative opportunities for maximizing long-term growth.
16:39 EDTPDLIPDL BioPharma to hold a conference call
Subscribe for More Information
January 29, 2016
14:39 EDTAROAeropostale by-law change suggests potential for 'go-private' deal, says Stifel
Stifel analyst Richard Jaffe noted that Aeropostale amended and restated its by-laws earlier this week so that any director, or the entire board, may be removed, with or without cause, by the holders of a majority of the shares, which he believes makes the possibility of the company getting bought out, perhaps in a "go-private" deal led by Sycamore, both easier and more likely. However, Jaffe keeps a Hold rating on shares as he believes the stock is fully valued based on its fundamentals.
January 27, 2016
11:20 EDTDKSBed Bath & Beyond slips after Citi, Keybanc both say sell
Home goods retailer Bed Bath & Beyond (BBBY) is declining in late morning trading after being downgraded to Sell-equivalent ratings at both Keybanc and Citi. WHAT'S NEW: KeyBanc analyst Bradley Thomas downgraded Bed Bath & Beyond to Underweight from Sector Weight after his firm's work on housing showed growth has slowed. The analyst noted that the home furnishings sector is growing increasingly competitive, and he took a more cautious view on Hardline retailers whose growth is predicated primarily on same-store sales. Thomas kept a $35 price target on shares of Bed Bath & Beyond. Citi analyst Kate McShane downgraded Bed Bath & Beyond to Sell from Neutral on expectations the retailer's earnings will continue to decline over the next two years. McShane also noted that competition in home furnishings remains intense, while Bed Bath's e-commerce operations continue to be unprofitable. McShane cut her price target for the shares to $37 from $51. OTHERS TO WATCH: The analysts, in their respective notes, also opined on Bed Bath & Beyond's peers. Keybanc's Thomas downgraded Haverty Furniture (HVT) and Pier 1 Imports (PIR) to Sector Weight from Overweight. Meanwhile, Citi's McShane recommended a pair trade of long Dick's Sporting Goods (DKS), which the firm is Overweight on due to valuation, and short Bed Bath & Beyond. PRICE ACTION: Shares of Bed Bath & Beyond are down 1.6% to $43.34, while Haverty Furniture and Pier 1 Imports are down 3.8% and 3.9%, respectively. Dick's Sporting Goods, meanwhile, is down 0.7% to $37.84.
10:00 EDTBHPOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Airlines (AAL) upgraded to Buy from Neutral at UBS... Armstrong World (AWI) upgraded on valuation at BB&T... Autoliv (ALV) upgraded to Outperform from Neutral at Baird... BHP Billiton (BHP) upgraded to Overweight from Equal Weight at Morgan Stanley... BorgWarner (BWA) upgraded to Outperform from Neutral at Baird... Boyd Gaming (BYD) upgraded on valuation at Sterne Agee CRT... CF Industries (CF) upgraded to Outperform from Underperform at CLSA... Deutsche Boerse (DBOEY) upgraded to Neutral from Underperform at Credit Suisse... Diamond Offshore (DO) upgraded to Neutral from Sell at Clarksons Platou... Exelon (EXC) upgraded to Neutral from Sell at Citi... FCB Financial (FCB) upgraded to Buy from Neutral at Guggenheim... Flushing Financial (FFIC) upgraded to Buy from Hold at Sandler O'Neill... Hawaiian Holdings (HA) upgraded to Buy from Hold at Deutsche Bank... Huntington Bancshares (HBAN) upgraded to Neutral from Underperform at Macquarie... Imperva (IMPV) upgraded to Outperform from Market Perform at JMP Securities... Lockheed Martin (LMT) upgraded to Outperform from Peer Perform at Wolfe Research... McDonald's (MCD) upgraded to Buy from Hold at Argus... Munich Re (MURGY) upgraded to Overweight from Equal Weight at Morgan Stanley... NextEra Energy (NEE) upgraded to Conviction Buy from Buy at Goldman... PG&E (PCG) upgraded to Buy from Neutral at Goldman... Panera Bread (PNRA) upgraded to Buy from Neutral at BTIG... Raptor Pharmaceuticals (RPTP) upgraded to Buy from Neutral at Citi... Siemens (SIEGY) upgraded to Equal Weight from Underweight at Barclays... Sprint (S) upgraded to Perform from Underperform at Oppenheimer... Stryker (SYK) upgraded to Buy from Hold at Brean Capital... Super Micro Computer (SMCI) upgraded to Positive from Neutral at Susquehanna... Talmer Bancorp (TLMR)upgraded to Outperform from Market Perform at Keefe Bruyette... Terex (TEX) upgraded to Neutral from Underweight at JPMorgan... Transocean (RIG) upgraded to Neutral from Sell at Clarksons Platou... Washington Trust (WASH) upgraded to Buy from Neutral at Compass Point... Yara (YARIY) upgraded to Buy from Hold at Berenberg.
06:46 EDTDKSBed Bath & Beyond downgraded to Sell from Neutral at Citi
Subscribe for More Information
06:14 EDTBHPBHP Billiton upgraded to Overweight from Equal Weight at Morgan Stanley
Subscribe for More Information
January 25, 2016
17:37 EDTBHPVale, BHP to be guarantors of any Samarco deal, Reuters says
Vale (VALE) and BHP Billiton (BHP) will be financial guarantors of any accord reached between Brazil and the two companies' Samarco joint venture, reports Reuters, citing statements from the country's attorney general Luis Adams. Reference Link
10:00 EDTHDOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: American Express (AXP) upgraded to Perform from Underperform at Oppenheimer... BankMutual (BKMU) upgraded to Outperform from Market Perform at Hovde Group... Black Hills (BKH) upgraded on acquisition at BMO Capital... Bruker (BRKR) upgraded to Buy from Hold at Cantor... Cedar Fair (FUN) upgraded to Conviction Buy from Buy at Goldman... Charles Schwab (SCHW) upgraded to Buy from Neutral at Nomura... Corporate Office Properties (OFC) upgraded to Buy from Neutral at Mizuho... Entegris (ENTG) upgraded on valuation, outlook at Pacific Crest... First Financial upgraded to Outperform from Market Perform at Keefe Bruyette... Goldman Sachs (GS) upgraded to Buy from Neutral at Nomura... Graphic Packaging (GPK) upgraded to Outperform from Neutral at Macquarie... Home Depot (HD) upgraded to Buy from Hold at Deutsche Bank... Intel (INTC) upgraded to Outperform from Neutral at Macquarie... J.B. Hunt (JBHT) upgraded to Buy from Hold at BB&T... Magna (MGA) upgraded to Buy from Neutral at Citi... Masco (MAS) upgraded to Buy from Hold at Evercore ISI... Mattel (MAT) upgraded to Conviction Buy from Buy at Goldman... O'Reilly Automotive (ORLY) upgraded to Buy from Hold at Deutsche Bank... PACCAR (PCAR) upgraded to Buy from Neutral at Citi... People's United (PBCT) upgraded to Neutral from Underweight at Piper Jaffray... Quality Systems (QSII) upgraded to Overweight from Neutral at Piper Jaffray... RadiSys (RSYS) upgraded to Buy from Hold at Needham... Standard Motor (SMP) upgraded to Buy from Neutral at CL King... Swedbank (SWDBY) upgraded to Hold from Underperform at Jefferies... Toll Brothers (TOL) upgraded to Strong Buy from Outperform at Raymond James... Voyager Therapeutics (VYGR) upgraded to Neutral from Sell at Chardan... Yahoo (YHOO) upgraded to Buy from Hold at Pivotal Research.
07:02 EDTCYTXCytori Therapeutics says Phase 3 STAR trial treats 20th patient
Cytori Therapeutics announced that its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 20th patient -- 25% of target enrollment. In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 10 patients and recommended that the study continue as planned. The 20 procedures, including the fat harvest from small volume liposuction and the finger injections have all been completed successfully and well tolerated. STAR is a randomized, placebo-controlled, double-blind, parallel group phase III FDA approved pivotal study investigating the efficacy and safety of Cytori Cell Therapy (ECCS-50) injected subcutaneously into the fingers of patients with impaired hand function from scleroderma. A total of 80 patients will be randomized with 40 receiving Cytori Cell Therapy and 40 receiving placebo. The double-blind period extends to 48 weeks. After all patients have completed 48 weeks follow-up, the placebo patients will be offered active treatment should they desire treatment and continue to qualify. The trial began enrollment in August 2015 with enrollment expected to be completed by mid-2016. The STAR trial follows the twelve patient SCLERADEC-I pilot trial in which one year post-treatment results were published in the August 2015 edition of the journal Rheumatology. The data indicated that a single administration of ECCS-50 was safe and that treated patients exhibited significant improvements in hand symptoms, function and Raynaud's Phenomena through one-year post-treatment.
06:15 EDTHDHome Depot upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Mike Baker upgraded Home Depot to Buy citing the recent pullback in shares and favorable industry dynamics. The home centers have the best fundamentals in hardline retail, Baker tells investors in a research note. He keeps a $135 price target on shares of Home Depot. The stock closed Friday up $2.55 to $122.77.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use